No Data
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 64%
FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Express News | FibroGen Initiated Restructuring Plan Following Negative Pamrevlumab Trial Data; Plan Includes 75% U.S. Workforce Reduction Affecting 127 Employees
FibroGen to Incur $16M-$18M Restructuring Charge Amid Layoffs
Express News | FibroGen : Majority of Restructuring Charges Expected in Second Half of 2024
Express News | FibroGen Inc: Estimates Non-Recurring Charges of $16-18 Million for Restructuring
No Data
My guess is they are going to keep their doors open just long enough to sell off what little owning interest they have in the two remaining collaborative drug candidates